Form 4: Royalty Pharma CFO Executes Planned Share Sale

Royalty Pharma EVP & CFO Terrance P. Coyne sold 34,791 Class A Ordinary Shares via a pre-arranged 10b5-1 trading plan.

Summary

• EVP & CFO Terrance P. Coyne sold a total of 34,791 Class A Ordinary Shares on April 28, 2026.
• The sales were executed at a weighted average price of $49.7784 per share.
• Transactions were conducted through two entities: TPC RP 2021, LLC (32,916 shares) and TPC RP EPA1 LLC (1,875 shares).
• The sales were performed under a Rule 10b5-1 trading plan adopted on August 8, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-planned 10b5-1 arrangement, which is a routine administrative action for executives.

Positives

• The transaction was executed under a pre-established 10b5-1 plan, indicating the sale was scheduled in advance rather than based on non-public information.

Negatives

• The sale represents a reduction in the executive's direct and indirect beneficial ownership of company stock.

Risks

• Future share price volatility may impact the value of remaining holdings held by the executive and associated family vehicles.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for corporate executives to manage personal liquidity and diversification, and generally does not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives at large-cap pharmaceutical and biotech firms to avoid potential conflicts of interest regarding insider trading regulations.

Related Party Transactions

• The reporting person holds interests in family vehicles TPC RP 2021, LLC and TPC RP EPA1 LLC, as well as holdings in RPI US Partners 2019, LP and Royalty Pharma Holdings Ltd.

Stakeholder Impact

• Minimal impact expected on shareholders as the sale was pre-planned and represents a small portion of the executive's total potential equity interest.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Royalty Pharma, RPRX, Insider Trading, Form 4, CFO, 10b5-1